
Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target
Adaptive Biotechnologies (ADPT) Analyst Ratings
Bulls say
Adaptive Biotechnologies is benefiting from a stronger clinical and reimbursement backdrop for clonoSEQ, with NCCN’s updated multiple myeloma guidelines explicitly naming it as the only FDA-cleared NGS MRD assay and expanding testing frequency, which should support materially higher utilization. The company also posted solid operating momentum, including Q2’26 revenue of $72M, MRD revenue of $66M, MRD volumes up 43% year over year, and adjusted EBITDA of -$0.7M, while management raised 2026 MRD revenue guidance to $268M-$278M. Longer term, its dominant position in a still underpenetrated heme MRD market, rising ASPs toward $1,400 in 2026 and $1,700-$1,800 over time, improving gross margins, and the planned separation of MRD from Immune Medicine all support a favorable fundamental outlook.
Bears say
Adaptive Biotechnologies is facing a negative fundamental setup because its core MRD growth depends on successful EMR integrations and broader community adoption, both of which could lag expectations and slow volume expansion. Competition is also a meaningful risk as more players may enter the under-penetrated heme market, while reimbursement, clinical guideline hurdles, and slower-than-expected customer adoption or product launches could further limit uptake of clonoSEQ. In addition, the Immune Medicine business may exceed burn targets and strain resources needed for MRD growth, and the planned separation by YE'26 is uncertain in timing and outcome despite the stock trading at a significant premium multiple.
This aggregate rating is based on analysts' research of Adaptive Biotechnologies and is not a guaranteed prediction by Public.com or investment advice.
Adaptive Biotechnologies (ADPT) Analyst Forecast & Price Prediction
Start investing in Adaptive Biotechnologies (ADPT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Adaptive Biotechnologies (ADPT) Forecast
Adaptive Biotechnologies (ADPT) Analyst Forecast & Price Prediction
Start investing in Adaptive Biotechnologies (ADPT)
Order type
Buy in
Order amount
Est. shares
0 shares